PMID- 12610718
OWN - NLM
STAT- MEDLINE
DCOM- 20030724
LR  - 20220318
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 166
IP  - 4
DP  - 2003 Apr
TI  - Switching patients to aripiprazole from other antipsychotic agents: a multicenter 
      randomized study.
PG  - 391-9
AB  - RATIONALE: Switching patients from one antipsychotic to another can lead to 
      tolerability problems or transient symptom exacerbations. It is important to 
      compare switching strategies to determine which methods produce the best possible 
      patient outcomes. OBJECTIVE: To investigate the efficacy, safety and tolerability 
      of three dosing strategies for switching chronic, stable patients with 
      schizophrenia from current oral antipsychotic monotherapy to once-daily oral 
      aripiprazole monotherapy. METHOD: Patients in this 8-week, open-label, outpatient 
      study were randomized to: 1). immediate initiation of 30 mg/day aripiprazole with 
      simultaneous immediate discontinuation of current antipsychotic; 2). immediate 
      initiation of 30 mg/day aripiprazole while tapering off current antipsychotic 
      over 2 weeks; or 3). up-titrating aripiprazole to 30 mg/day over 2 weeks, while 
      simultaneously tapering off current antipsychotic. Efficacy assessments included 
      PANSS, CGI-S, and CGI-I scores. Safety assessments included: adverse events (AEs) 
      recording, evaluation of extrapyramidal symptoms (EPS), vital signs, ECG, and 
      clinical laboratory tests. RESULTS: Efficacy with aripiprazole was maintained 
      during the study with numerical improvements compared with baseline in all three 
      groups. The overall incidence of AEs was broadly comparable across all groups, 
      and AEs were generally mild to moderate in severity and time-limited. 
      Discontinuations due to AEs were comparable across the groups. No deterioration 
      in EPS occurred in any group. The reduction in body weight and plasma prolactin 
      levels following switch to aripiprazole were comparable across the three groups. 
      CONCLUSION: Any of the three strategies evaluated can be used safely for 
      switching patients to aripiprazole from antipsychotic monotherapy. Furthermore, 
      patients' symptoms may continue to improve after switching to aripiprazole.
FAU - Casey, Daniel E
AU  - Casey DE
AD  - Mental Health Division (P3MIRECC), VA Medical Center, 3710 SW US Veterans 
      Hospital Road, Portland, OR 97239, USA. daniel.casey@med.va.gov
FAU - Carson, William H
AU  - Carson WH
FAU - Saha, Anutosh R
AU  - Saha AR
FAU - Liebeskind, Amy
AU  - Liebeskind A
FAU - Ali, Mirza W
AU  - Ali MW
FAU - Jody, Darlene
AU  - Jody D
FAU - Ingenito, Gary G
AU  - Ingenito GG
CN  - Aripiprazole Study Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20030228
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Piperazines)
RN  - 0 (Quinolones)
RN  - 82VFR53I78 (Aripiprazole)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Aripiprazole
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Male
MH  - Piperazines/administration & dosage/adverse effects/*therapeutic use
MH  - Quinolones/administration & dosage/adverse effects/*therapeutic use
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
EDAT- 2003/03/01 04:00
MHDA- 2003/07/25 05:00
CRDT- 2003/03/01 04:00
PHST- 2002/05/23 00:00 [received]
PHST- 2002/11/06 00:00 [accepted]
PHST- 2003/03/01 04:00 [pubmed]
PHST- 2003/07/25 05:00 [medline]
PHST- 2003/03/01 04:00 [entrez]
AID - 10.1007/s00213-002-1344-3 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2003 Apr;166(4):391-9. doi: 10.1007/s00213-002-1344-3. 
      Epub 2003 Feb 28.